Aims And Background: Recent publications of breast cancer classification based on gene expression profile analyses indicate that medullary breast carcinomas (MBC) may be considered part of the basal-like carcinoma spectrum made up of ER-negative, PR-negative and HER-2-negative cells ("triple-negative phenotype"). On the other hand, there are also data showing that a proportion of MBC and atypical MBC (AMBC) is ER, PR and/or HER-2 positive. Therefore, we have decided to immunohistochemically analyze ER, PR, HER-2 and basal/myoepithelial markers CK 5/6, p63 and EGFR expression in our archival paraffin-embedded MBC and AMBC samples from 48 patients.
Methods: Immunohistochemical evaluation of samples which were derived from patients operated on at our two hospitals between 1999 and 2005.
Results: Typical MBC was found in 39 patients and AMBC in 9 patients. The patients ranged in age from 32 to 84 years (median 55). Modified radical mastectomy with axillary dissection was performed in 30/48 patients (63%) while breast segmentectomy with axillary dissection was performed in 18/48 patients (37%). Metastases in axillary lymph nodes were observed in 15/48 patients (31%). ER positivity was present in 3/48 patients (6%), PR positivity in 8/48 (17%), and a positive HER-2 reaction was present in 14/48 patients (29%). CK 5/6 was positive in 20/48, p63 in 24/48 and EGFR in 8/48 patients. Adjuvant therapy was applied in all but 2 patients. Alive were 45/48 (94%) of patients. With the exception of PR expression, 39 patients with typical MBC and 9 patients with AMBC were comparable in the analyzed parameters. Positive HER-2 antigen expression in the analyzed sample was not found to be associated to a statistically significant degree with the MBC or AMBC histological tumor type, tumor size, axillary lymph node metastases, ER and PR status nor with patient survival.
Conclusions: The data from our study seem to be generally comparable with the relatively scarce published data on clinicopathological parameters of MBC and AMBC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/030089160809400611 | DOI Listing |
PLoS Pathog
January 2025
Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
Expansion of atypical memory B cells (aMBCs) was demonstrated in malaria-exposed individuals. To date, the generation of P. vivax-specific aMBCs and their function in protective humoral immune responses is unknown.
View Article and Find Full Text PDFTher Adv Med Oncol
November 2024
Department of Medical Oncology and Hematology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA.
Int J Biol Macromol
December 2024
Cellulose & Composites Research Group, Department of Materials Science and Metallurgical Engineering, Indian Institute of Technology, Hyderabad, Kandi, 502285 Sangareddy, Telangana, India. Electronic address:
Bacterial cellulose (BC) stands out as a promising candidate for novel drug delivery systems due to its micro-mesoporous nanofibrous interconnected structure. However, its performance is limited by the burst release of hydrophilic drugs and lower incorporation of the less water-soluble or insoluble drugs. In this study, we explored its potential as a drug carrier for two distinct types of drugs: Diclofenac sodium and Simvastatin, representing water-soluble and water insoluble compounds, respectively.
View Article and Find Full Text PDFTarget Oncol
May 2024
Faculty of Medicine, University of British Columbia, and BC Cancer, 600 W 10th Ave, Vancouver, BC, V5Z 1M9, Canada.
Background: Palbociclib in combination with endocrine therapy is approved for treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. In addition to clinical trials, several real-world studies have evaluated the effectiveness of palbociclib. With increased life expectancy in the general population, breast cancer in older women is also expected to increase.
View Article and Find Full Text PDFFront Oncol
December 2023
Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!